AI-driven ophthalmic monitoring platform tracking presbyopia drug response and visual acuity trends.
Validated on That's Missing platform | Status: Active Opportunity
Market Catalyst & News Trigger
"Viatris secures FDA approval for RYZUMVI, first drug for presbyopia"
Source: NewsAPI
| Published: 10/17/2026
The Workflow Friction
Ophthalmologists lack standardized digital protocols to monitor RYZUMVI efficacy and adverse reactions in real-time.
Problem Summary
Real-world problem signal validation.
One-Shot MVP Builder Blueprint (48 Hours)
Patient app logging daily visual clarity scores synced to clinician dashboard for RYZUMVI cohort analysis.
Recommended Developer Tech Stack
- React Native
- AWS HealthLake